Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELCADEXA: Velcade and Dexamethasone in Untreated Multiple Myeloma
NCT00391157Phase 2Completed
- Sponsor
- Fundación PETHEMA
- Start
- Aug 2005
- Primary completion
- Jun 2007
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM), sponsored by Fundación PETHEMA. Primary endpoint: Overall Response Rate at 6 months. Started Aug 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00391157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00391157.